Her other re- sponsibilities include serving as an associate editor for the American Heart Journal, and as a member of the editorial boards of Kidney360, the Clinical Journal of the American Society of Nephrology, and the Journal of Human Hypertension. Consultancy: Bayer, Gilead, Janssen Research and Develop- ment, Novo Nordisk, Tricida, and Vascular Dynamics Advisory boards: AstraZeneca and Fresenius Medical Care Renal Therapies Group Grant/research support: AstraZeneca and Satellite Healthcare www.kidney-international.org biographic and disclosure information William C. Cushman, MD, FAHA, FACP, is the medical director of the Department of Preventive Medicine, and a professor of preventive medicine, medicine, and physiology at the Uni- versity of Tennessee Health Science Center (UTHSC) in Memphis, TN, USA. He was trained at the University of Mississippi School of Medicine in Jack- son, Mississippi, USA. After serving on the faculty there and as staff at the Department of Veterans Affairs (VA) Medical Center, he moved to the UTHSC and the VA in Memphis, Tennessee. He retired from the VA in 2020 to assume his current position at UTHSC. Dr. Cushman is recognized for his expertise in hyperten- sion. He was a VA champion for the 2014 and 2020 US VA/ DoD Hypertension Clinical Practice Guideline committees, and was on the leadership committees for the Joint National Committee (JNC) 7 and JNC 8 US hypertension guidelines. He has participated in the leadership for many National Heart, Lung and Blood Institute, VA, and industry-sponsored clinical trials in hypertension and diabetes. He has authored more than 300 journal article and book chapter publications and has received several awards, including the 2010 VA Clinical Science Research and Development Barnwell Award, the 2017 Inter-American Society of Hypertension Lifetime Achievement Award, and the 2018 American Heart Associa- tion s Council on Hypertension Irvine Page-Alva Bradley Lifetime Achievement Award. 